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A B S T R A C T
The aim of this crossectional study was to investigate the relationship between pepsin concentration in saliva and the
occurrence of tracheoesophageal fistula (TEF) complications and voice prosthesis (VP) complications, after total laryn-
gectomy and VP implantation. We assessed the concentrations of pepsin in the saliva of 41 laryngectomized patients and
correlated it with the incidence of TEF complications (periprostethic leakage, atrophy, esophageal mucosa hypertrophy,
granulations, fistula enlargement, and VP dislocation), VP complications (transprosthetic leakage, Candida infection)
and voice quality. Pepsin levels were measured by enzyme-linked immunoadsorbent assay (ELISA). Voice quality was as-
sessed by Harrison-Robilard – Schultz (HRS) scale. In all, 17 (42%) patients had complications. All of them had TEF
complications, whereas VP complication, together with TEF was found in 9 (22%) patients. We found no significant cor-
relation between adjuvant radiotherapy and TEF complications. Most of patients, 30 (73%), had positive pepsin level in
saliva. Median value of pepsin concentration in all patients was 4.8 (range 81.7). Median pepsin concentration was
higher in patients free of TEF or VP complications (6.6, range 81.7 vs. 3.2, range 19.3) but that difference was not statis-
tically significant (Mann-Whitney test, Z –1.562, p=0.118). In addition, statistically insignificant negative correlation
between pepsin levels and voice quality measured by HRS scale (Spearman’s rho, p>0.05). Although reflux was proposed
as cause of TEF complications and pepsin has been proven as a most sensitive and specific marker of ekstraesophageal
reflux, we did not find any statistically significant correlation between pepsin levels and occurrence of TEF or VP compli-
cations.
Key words: tracheoesophageal fistula, reflux, pepsin, laryngectomy
Introduction
Voice prosthesis (VP) insertion into tracheoesopha-
geal fistula (TEF) is a golden standard in voice rehabili-
tation in patients who have undergone total laryngec-
tomy. In the last 40 years easily replaceable prosthesis
with different valve design have been developed to facili-
tate satisfactory voice production and prevent aspiration
of saliva. Still, several complications regarding VP and
TEF have been described in current literature1,2. Compli-
cations related to TEF are periprostethic leakage, atro-
phy, esophageal mucosa hypertrophy, granulations, fis-
tula enlargement, and VP dislocation. VP complications
are transprosthetic leakage and Candida infection. Pres-
ervation of TEF and VP can be very demanding not only
to maintain patient’s communication ability and quality
of life but to prevent very serious complications due to an
aspiration. It was purposed that these complications can
be associated with reflux of gastric contents to upper
esophagus and TEF3,4. Lorenz and al have found higher
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occurrence of TEF enlargment and reduction in life span
of VP in patients with more severe reflux disease con-
firmed by 24-hour dual-probe pH monitoring3. Some
studies demonstrated that in majority of patients, the
symptoms associated with TEF complications can be im-
proved or cured by rigorous anti-reflux treatment with
proton pump inhibitors (PPIs)5,6. Bock and al confirmed
reflux with pepsin deposition into the TEF in majority of
laryngectomy patients5. Pepsin is a reliable biological
marker of extraesophageal reflux (EER)7,8. Detection of
reflux with pepsin assay is noninvasive method and it is
easily obtainable from fluid secretions like saliva or spu-
tum7. The aim of this crossectional study was to investi-
gate the relationship between pepsin concentration in sa-
liva and the occurrence of tracheoesophageal fistula (TEF)
complications and voice prosthesis (VP) complications in
patients who have undergone total laryngectomy.
Patients and Methods
Forty one adult patients at the ENT Department, »Dr.
J. Ben~evi}« General Hospital, Slavonski Brod and ENT
University Departments, Zagreb and Rijeka University
Hospital Centres who underwent total laryngectomy and
insertion of the voice prosthesis were recruited to partici-
pate at this study. Median age of all patients was 60 years
(50–76), and proportion of males was 93%. Before partici-
pation, each study subject signed an informed, written
conset that was approved by ethics committee of »Dr. J.
Ben~evi}« General Hospital, ethics committee of Zagreb
University Hospital Center and ethics committee of Rije-
ka University Hospital Center. All patients used voice
prosthesis either from Atos Medical Inc (Horby, Sweden)
or InHealth technologies (Carpinteria, USA). Patients
who were on IPP therapy were excluded from the study.
Subjects were given sterile tubes and 3–5 ml of saliva was
collected in the morning. Pepsin levels in saliva were as-
sayed by Human Pepsin (PG) ELISA kit (Causabio Bio-
tech Co., Ltd, P.R.C.) according to manufacturers proto-
col. Undiluted saliva samples were assayed and pepsin
results were expressed in ng/ml. Positive test for pepsin
was considered to be higher than 1.2 ng/ml. Concentra-
tions of pepsin in the saliva were compared according to
incidence of TEF complications (periprostethic leakage,
atrophy, esophageal mucosa hypertrophy, granulations,
fistula enlargement, and VP dislocation), VP complica-
tions (transprosthetic leakage, Candida infection) and
voice quality. Voice quality was assessed by Harrison-
-Robilard – Schultz (HRS) scale (Table 1).
Statistical analysis with chi square, non-parametric
Mann-Whitney test (for data with abnormal distribu-
tion), Student T-test, and nonparametric correlation
Spearmann’s rho test was performed using statistical
software SPSS for Windows, version 11.0.3, Chicago, IL,
USA. Statistical significance was set to p<0.050.
Results
Among 41 investigated patients, there were 17 pa-
tients (42%) with complications. All patients with com-
plications had at least one of the TEF complications,
whereas VP complication was present together with TEF
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TABLE 1
HARRISON-ROBILLARD SHULTZ SCALES USED FOR VOICE QUALITY ASSESSMENT
Scale Answer Points
A. Use
Degree of use of
tracheoesophagal
speech
Never uses tracheoesophageal speech (0%) 1
Uses tracheoesophageal speech less than 50% of the time 2
Uses tracheoesophageal speech 50% to 80% of communicative attempts 3
Uses tracheoesophageal speech manually occluded as main means of communication 4
Uses tracheoesophageal speech with tracheostoma valve as main means of communication 5
B. Quality
The ease of production
and intelligibility of
speech as determined
by fluency and ability
to occlude
Unable to get sound, no use of pulmonary air for speech 1
Voice is too strained or too breathy to permit functional use in conversation (may interfere
with intelligibility), includes whispered speech
2
Stoma, more often than not, is poorly occluded with resultant air escape that interferes with
intelligibility or is distraction to the listener
3
Voice is mildly stained or mildly breathy, but continuous use in conversation is possible,
occlusion is generally good, speech is intelligibile.
4
Voice is easly produced, occlusion is good, speech is intelligibile 5
C. Care* Unable to do any of 4 behaviours 1
Independent for any 1 of 4 behaviours 2
Independent for any 2 of 4 behaviours 3
Independent for any 3 of 4 behaviours 4
Independent for any 4 of 4 behaviours 5
*Patient independence of medical care or other health care professionals (speech/language pathologist, nurse, community worker) for 4
behaviours: remove and insert prosthesis, clesn and sterilize prosthesis, recognize problems and seek help immediately, and order suplies
U:\coll-antropolo\coll-antro-(Suppl 2)-2012\07 Djanic Hadzibegovic.vp
7. prosinac 2012 10:07:52
Color profile: Generic CMYK printer profile
Composite  150 lpi at 45 degrees
complication in 9 patients (22%). The most common com-
plication was granulation of the tracheal mucosa fol-
lowed by transprostetic and periprostetic leakage and at-
rophy of tracheoesophageal wall (Table 2). There were no
differences between patients with complications and pa-
tients free of complication regarding relevant clinical
characteristics, except for secondary insertion of VP, mio-
tomy and time since last VP exchange. Patients with sec-
ondary VP insertion had significantly higher proportion
of TEF complications than patients with primary VP in-
sertion (chi square, p=0.029). Patients who underwent
miotomy during laryngectomy had significantly lower
proportion of TEF and VP complications (chi square,
p=0.039). In addition, patients with longer time since
last VP exchange had more frequent TEF and VP compli-
cations (Mann-Whitney test, p=0.011). More than half of
patients underwent adjuvant neck radiation, but there
were no differences in proportions of complications re-
garding referral to adjuvant radiotherapy (Table 3).
Positive test for pepsin was found in 30 patients
(73%). There were no significant differences in propor-
tions of complications between pepsin negative and pep-
sin positive patients (Table 4). Median pepsin value in all
investigated patients was 4.8 ng/ml (range <1.2 and 81.7
ng/ml). Median pepsin value was higher in patients free
of complications (6.6 ng/ml vs. 3.2 ng/ml) but that differ-
ence was not statistically significant (Mann-Whitney test,
Z=–1.562, p=0.118). There were no differences in me-
dian pepsin value between patients in regard to myo-
tomy, alcohol abuse and radiotherapy. Voice quality mea-
sured with HRS scale A and C correlated negatively with
pepsin concentration in saliva, whereas weak positive
correlation was found for HRS scale B results and pepsin
levels. Correlations were not statistically significant
(Spearmann’s rho, –0.151, –0.125, and 0.071, respec-
tively, p>0.050). There were no significant differences in
voice quality measured by HRS scales between patients
with complications and patient free of complications (Ta-
ble 5), except for 2 patients with hypertonycity who had
very poor voice quality.
Discussion
Simple surgical technique of insertion of VP into TEF
and rapid and successful voice rehabilitation makes this
method a treatment of choice in voice rehabilitation after
total laryngectomy. However, there is still significant
number of complications reported in the literature to
date and the incidence varies from 10–50%1,3,9. We have
found 42 % of patients with TEF and VP complications.
Periprostetic leakage in association with moderate fis-
tula enlargement was reported as the most common
complication3. In our study, the most common complica-
tion was granulation of the tracheal mucosa followed by
transprostetic and periprostetic leakage and atrophy of
tracheoesophageal wall. There are several risk factors
that are contributing to TEF and VP complications de-
scribed in the literature, such as arterial hypertension,
diabetes mellitus, myotomy during total laryngectomy
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TABLE 2
FREQUENCIES OF DIFFERENT TEF AND VP COMPLICATIONS
AMONG PATIENTS WITH COMPLICATIONS
Complications, N (%) patients N (%)
TEF complications
17 (100) patients
Periprosthetic leakage 5 (24)
TEF dilatation 1 (4.5)
VP dislocation 2 (10)
Granulations 7 (33)
Atrophy 5 (24)
Esophageal hypertrophy 1 (4.5)
Total 21 (100)
VP complications
9 (53) patients
Candida infection 4 (40)
Transprosthetic leakage 6 (60)
Total 10 (100)
TABLE 3
DIFFERENCES IN RELEVANT CLINICAL CHARACTERISTICS
AMONG 41 INVESTIGATED PATIENTS REGARDING PRESENCE
OF TEF AND VP COMPLICATIONS
Clinical characteristic
Patients, N (%)
Compli-
cations
No compli-
cations
Total
Age, years, median (range) 63 (51–76) 61 (50–75) 60 (50–76)
Male gender 15 (40) 23 (60) 38 (100)
History of alcohol abuse 7 (41) 10 (59) 17 (100)
Current smoker 2 (100)* 0 (0) 2 (100)
Diabetes mellitus 2 (50) 2 (50) 4 (100)
Radical neck dissection 5 (35) 9 (65) 14 (100)
Selective neck dissection 4 (80) 1 (20) 5 (100)
Miotomy 2 (15)* 11 (85) 13 (100)
Adjuvant chemotherapy 1 (33) 2 (67) 3 (100)
Adjuvant radiotherapy 9 (36) 16 (64) 25 (100)
Time since TEF creation,
months, median (range)
29 (3–83) 25.5 (3–84) 25.5 (3–84)
Time since last VP ex-
change, months, median
(range)
3 (1–8)† 1 (0.3–8) 2 (0.3–8)
Secondary VP insertion 8 (73)* 3 (27) 11 (100)
* c2, p<0.050
† Mann-Whitney test, Z= –2.557, p<0.050
TABLE 4
RELATIONSHIP BETWEEN HUMAN PEPSIN ELISA TEST AND
PROPORTION OF COMPLICATIONS
Complications
Human Pepsin ELISA test, N (%)*
Negative Positive
No 5 (21) 19 (79)
Yes 6 (35) 11 (65)
Total 11 (27) 30 (73)
* c2, p=0.476
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and TEF formation, postoperative radiotherapy, trauma
during prosthesis replacement and EER1,3,6,9. In our study,
there were no differences between patients with and
without complications regarding arterial hypertension
and diabetes mellitus. Patients who did not undergo
mytomy had higher proportion of complications which
was probably a consequence of periprostetic leakage and
EER caused by pressure peak in hypopharyngeal area
during swallowing9. Patients who underwent secondary
VP insertion had higher proportion of complications
probably because they also did not undergo myotomy.
Loss of the larynx and resection of the laryngeal
nerves cause changes in esophageal motility reflux bar-
riers10, 11. Patients who have undergone total laryngec-
tomy have higher incidence of gastroesophageal reflux
and EER12. Although it has been proven that postopera-
tive radiotherapy reduces esophageal clearence and de-
crases neutralizing effects of saliva13 we did not find any
differences in complication rates in regard to postopera-
tive radiotherapy. There are also several research groups
that have reported similar results1,3,9,14. Esophageal mu-
cosa is resistant to physiological reflux of gastric fluid
but pathological reflux can cause different changes from
erosion to adenocarcinoma. Pharyngeal, laryngeal and
tracheal mucosa has no natural barriers to gastric fluid
and even small amounts of gastric content, 6–10 reflux
events in 24 hours, can cause a massive damage to pha-
ryngeal or tracheal mucosa15,16. Mucosa can be damaged
by low pH values of gastric acid, pepsin, pancreatic en-
zymes and bile acid15–17. Reflux of gastric fluid into upper
esophagus after total laryngectomy would not present a
problem if there would not be any communication be-
tween esophagus and airway. But, with TEF formation
direct communication between esophagus and trachea is
made. Influence of reflux on TEF and VP has been dem-
onstrated by only three working groups to date2,4,6. The
gold standard for diagnosis of EER today is still 24 hour
double – probe pH monitoring, although it has been
shown to be lacking in reproducibility18–21. It is also in-
capable of detecting nonacidic gastric reflux, which is
asocciated with airway disease22,23. After gastric acid,
pepsin is the most studied gastric component. Pepsin is
though to cause damage by its proetolytic activity digest-
ing the structures that maintain cohesion between cells.
It is maximally active at pH 2.0, but it can also cause
damage with higher pH up to 6.5 (mean pH of laryngo-
pharynx is 6.8), when is completly inactivated but not
irreversibly24. Thus it can be reactivated by a decrease in
pH. Pepsin is not irreversibly inactivated until pH 824.
Recent studies by Johnston and all have demonstrated
that pepsin is also taken up by hypopharyngeal and la-
ryngeal epithelial cells by receptor-mediated endocyto-
sis25, 26. They have also shown that pepsin at pH 7 signifi-
cantly alters the expression levels of multiple genes im-
plicated in stress and toxicity, induces pro-infalmmatory
cytokine gene expression, and alters the expression of 27
genes implicated in carcinogenesis16. Pepsin has also
been proven to be the most sensitive and specific marker
of EER8. It can be detected with several different meth-
ods such as ELISA, enzymatic pepsin assay or Western
blot analysis8. Detection of pepsin is a noninvasive meth-
od and effective in diagnosis of EER from easily obtain-
able fluid secretions like saliva or sputum8,27. Bock et al.
have found that reflux with subsequent pepsin deposi-
tion into TEF tract occurs in majority of laryngectomy
patients4. We have found positive test for pepsin in saliva
in 73% of patients which proves EER in majority of pa-
tients after total laryngectomy. The expected life span of
VP recommended by manufactures is 3 months. There is
evidence that supraesophageal or EER reflux is associ-
ated with reduced life span of voice prosthesis, with fis-
tula enlargement, increased granulation tissue forma-
tion, periprostetic leakage and increased crycopharyn-
geal stenosis or sapasm2,6. Our study has demonstrated
that the median life span of VP in patients without com-
plications was only 1 month which could probably mean
that patients require more frequent VP exchange. We did
not find any significant difference in proportions of com-
plications between pepsin positive and pepsin negative
patients. In addition, median pepsin value did not differ
significantly between patients with and without compli-
cations. These results were unexpected but suggest that
further studies of the impact of pepsin and EER on TEF
and VP are necessary. Voice quality measured by HRS
scale was more than satisfactory and complications or
pepsin levels did not influence voice quality.
Conclusion
We demonstrated that pepsin was present in saliva of
majority of patients, suggesting ongoing reflux in laryn-
gectomized patients. Although reflux was proposed to be
associated with TEF complications, and pepsin proven as
a most sensitive and specific marker of EER, we did not
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TABLE 5
VOICE QUALITY MEASURED BY HRS SCALES REGARDING
PRESENCE OF VP COMPLICATIONS
Voice
quality
test
Complications
No
complications
Total
N (%)
Median
score
N (%)
Median
score
N (%)
Median
score
HRS A
1 0 (0)
4
1 (4)
4
1 (2)
4
2 3 (18) 2 (8) 5 (12)
3 0 (0) 2 (8) 2 (5)
4 11 (18) 16 (62) 27 (66)
5 3 (64) 3 (13) 6 (14)
HRS B
1 1 (6)
5
1 (4)
5
2 (5)
5
2 2 (12) 3 (12) 5 (12)
3 1 (6) 0 (0) 1 (2)
5 3 (17) 4 (17) 7 (17)
4 10 (59) 16 (67) 26 (64)
HRS C
1 0 (0)
4
2 (8)
4
2 (5)
4
2 0 (0) 0 (0) 0 (0)
3 0 (0) 3 (13) 3 (7)
4 16 (94) 19 (79) 35 (85)
5 1 (6) 0 (0) 1 (3)
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find any statistically significant correlation between pep-
sin levels and occurrence of TEF or VP complications so
further studies of the impact of pepsin and EER on TEF
and VP are warranted.
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RAZINA PEPSINA U SLINI BOLESNIKA S KOMPLIKACIJAMA TRAHEOEZOFAGEALNE
FISTULE I GOVORNE PROTEZE
S A @ E T A K
Cilj ovog istra`ivanja bio je prou~iti odnose koncentracije pepsina u slini i u~estalosti pojave komplikacija traheoezo-
fagelane fistule (TEF) i komplikacija govorne proteze (GP) kod bolesnika s postavljenom GP nakon totalne laringek-
tomije. U istra`ivanje je bio uklju~en 41 bolesnik ~ije su razine koncentracije pepsina u slini uspore|ene s pojavom TEF
komplikacija (curenje oko proteze, atrofija, hipertrofija sluznice jednjaka, granulacije, pove}anje fistule i dislokacija
GP), komplikacija GP (curenje kroz GP, infekcija Candidom) i kvalitetom glasa. Koncentracija pepsina u slini mjerena je
»enzyme-linked immunoadsorbent assay« (ELISA) metodom. Kvaliteta glasa odre|ena je prema Harrison-Robilard –
Schultz (HRS) skali. Ukupno 17 (42%) bolesnika imalo je komplikaciju. Svi su imali komplikaciju TEF, dok je 9 (22%)
imalo i komplikaciju GP. Nismo na{li zna~ajnu razliku u pojavi komplikacija TEF me|u bolesnicima koji su primili
adjuvantu radioterapiju i koji nisu primili adjuvantu radioterapiju. Ve}ina bolesnika, 30 (73%), ima pozitivnu razinu
pepsina u slini. Medijan koncentracije pepsina u slini svih bolesnika je 4,8 (raspon 81,7). Medijan koncentracije pepsina
bio je vi{i kod bolesnika bez komplikacije TEF i GP (6,6, raspon 81,7 vs. 3,2, raspon 19,3) ali razlika nije statisti~ki
zna~ajna (Mann-Whitney test, Z –1,562, p=0,118). Tako|er je na|ena negativna korelacija izme|u razine pepsina i kva-
litete glasa, ali nije bila statisti~ki zna~ajna (Spearman’s rho, p>0,05). Iako se smatra kako ekstraezofagealni refluks
`elu~anog sadr`aja, ~iji je najosjetljiviji marker razina pepsina, doprinosi pojavi komplikacija TEF i GP ovim istra`i-
vanjem nije na|eno zna~ajne veze izme|u razine pepsina i u~estalosti komplikacija TEF i GP.
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